Acta medica Indonesiana最新文献

{"title":"Risk Factors of Coronary In-Stent Restenosis in Drug-Eluting Stent: A Systematic Review and Meta-Analysis.","authors":"Hotmauli Siahaan, Hari Basuki Notobroto, Yudi Her Oktaviono, Paulus Parholong Siahaan, David Setyo Budi, Rizky Novita Anjaswanti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In-stent restenosis (ISR) is an event of coronary atherosclerosis re-budling following the stent implantation in percutaneous coronary intervention. The events of ISR have been significantly reduced since the introduction of drug-eluting stents. However, ISR could still occur, and factors affecting the incident have not yet been discovered. This study aims to evaluate the risk factors of coronary in-stent restenosis in drug-eluting stents.</p><p><strong>Methods: </strong>Studies on the factors and risks of ISR in patients with drug-eluting stents were systematically searched in databases (PubMed, ScienceDirect, Springer, Google Scholar, and ProQuest) on September 20th, 2023. The odds ratio (OR) and mean difference (MD) were analyzed using Review Manager 5.4.</p><p><strong>Results: </strong>Diabetes mellitus (OR 1.73 [95%CI 1.56, 1.91] p < 0.00001) and smoking (OR 1.24 [95%CI 1.13, 1.36] p<0.0001) are the patients' clinical characteristics that are associated with ISR in DES. It is closely related to the contribution of diabetes mellitus in promoting platelet adhesion and smoking in enhancing intimal hyperplasia. As in the angiography characteristics, stent lesion at LAD (OR 1.20 [95%CI 1.07, 1.35] p = 0.002) and stent length (MD 3.61 [95%CI 1.81, 5.42] p < 0.0001) are correlated with the events of ISR. Every millimeter excess of stent length significantly increases the risk of ISR. Therefore, reducing the excess stent length may contribute to the reduced risk of ISR in DES.</p><p><strong>Conclusion: </strong>The identification of risk factors contributing to ISR in DES may help cardiologists modify the attributable factors and prevent the occurrence of ISR.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 2","pages":"153-166"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Co-existence of Drug-Susceptible Lung Tuberculosis and Drug-Resistant Pleural Tuberculosis: A Rare Case Presentation of Dual Infection.","authors":"Herikurniawan Herikurniawan, Joanna Audrey, Mira Yulianti, Ni Nyoman Indira, Cleopas Martin Rumende","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tuberculosis (TB) has become one of the global burdens of disease, with increasing morbidity and mortality every year. Tuberculosis can affect not only the lungs but also the extrapulmonary organs. The prevalence of drug-resistant tuberculosis (DR-TB) is rising and has caused a higher mortality rate than drug-susceptible tuberculosis (DS-TB). This article presents a patient with a rare co-infection of pulmonary DS-TB and pleural DR-TB. Pulmonary and pleural TB (pTB) was diagnosed using the Xpert MTB/RIF assay. The patient was treated with an individualized DR-TB regimen and recovered.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 2","pages":"237-240"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Palliative Care on Quality of Life and Cortisol Levels in HIV/AIDS Patients with Anxiety.","authors":"Wiwiek Indriyani Maskoep, Siti Qamariyah Khairunisa, Brian Eka Rachman, Pauline Ciuputri, Fhahira Rizkhika Admadiani, Sarah Fitria Andini, Tri Pudi Asmarawati, Nasronudin Nasronudin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Individuals with HIV/AIDS often experience significant physical and mental burdens. Palliative care has emerged as a means to improve the quality of life for people living with HIV/AIDS (PLWHA). This study aims to determine the effect of palliative care on the quality of life and psychoneuroimmunoendocrine aspects in PLWHA, particularly those suffering from anxiety, as indicated by cortisol hormone levels.</p><p><strong>Methods: </strong>A total of 30 PLWHA with anxiety were selected based on inclusion and exclusion criteria. This study employed a quantitative design with a quasi-experimental one-group pre-test and post-test approach. The data were analyzed using descriptive statistics and a paired t-test to assess the impact of the intervention on quality of life and cortisol hormone levels.</p><p><strong>Results: </strong>The findings indicated a significant improvement in quality of life following palliative care (p = 0.000, p < 0.05). The cortisol levels in PLWHA with anxiety decreased following palliative care; however, the reduction was not statistically significant, suggesting that palliative care had no measurable impact on cortisol levels post-intervention (p = 0.845, p > 0.05).</p><p><strong>Conclusion: </strong>Palliative care significantly enhances the quality of life in PLWHA. However, it does not lead to a statistically significant reduction in cortisol hormone levels before and after the intervention. Factors such as patient compliance with the palliative care plan and the influence of efavirenz on cortisol levels in PLWHA are likely contributing to these results.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 2","pages":"212-221"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation Between Angiotensin II Levels and Homeostatic Model Assessment of Insulin Resistance in Normotensive Young Adults with a Family History of Essential Hypertension.","authors":"Stella Palar, Syarif Bakri, Haerani Rasyid, Idar Mappangara","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>A family history of hypertension increases the risk of renin-angiotensin-aldosterone system activation, insulin resistance, and vascular inflammation, contributing to cardiovascular disease. Early vascular disturbances, marked by angiotensin II and insulin resistance assessed through the homeostatic model assessment of insulin resistance (HOMA-IR), play crucial roles in hypertension development. This study aims to determine the comparison and correlation between Ang II levels and HOMA-IR in normotensive young adults with or without offspring hypertension.</p><p><strong>Methods: </strong>We conducted this cross-sectional study by recruiting fifty normotensive participants, who were categorized into two groups: normotensive young adults who are offspring of parents with essential hypertension (case) and those who are not (control). The serum Ang II and HOMA-IR were measured. The comparative analysis was conducted using the Mann-Whitney test, and correlations were evaluated using Spearman's test.</p><p><strong>Results: </strong>Among the 50 subjects (25 cases and 25 controls), a significant difference was observed in Ang II levels (p = 0.010), whereas HOMA-IR (p = 0.206) showed no notable difference between case and control. Notably, a positive correlation between Ang II and HOMA-IR (r = 0.554; p = 0.004) was observed in the case group, while the control group exhibited an insignificant correlation (r = -0.089; p = 0.671).</p><p><strong>Conclusion: </strong>There are marked differences in Ang II levels between normotensive young adults with a family history of essential hypertension and those without such history. Additionally, a significant correlation was found between Ang II and HOMA-IR in normotensive young adults who have a family history of essential hypertension.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 2","pages":"222-227"},"PeriodicalIF":0.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polypharmacy and the Risk of Adverse Drug Reactions in the Elderly at a Tertiary Referral Hospital in Indonesia: Assessing the Applicability of the GerontoNet Score.","authors":"Nafrialdi Nafrialdi, Arief Kurniawan Jamal, Harri Hardi, Reni Widyastuti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Geriatric patients are often subject to polypharmacy, increasing their risk of adverse drug reactions (ADRs). This study evaluated polypharmacy practices, ADR incidence, predictive factors, and the applicability of the GerontoNet Score at a tertiary referral teaching hospital in Indonesia.</p><p><strong>Methods: </strong>This retrospective study included 340 geriatric inpatients at Dr. Cipto Mangunkusumo Hospital, Jakarta, in 2023. The relationship between demographic data, comorbidities, number of drugs used, and ADR events was analyzed using the Chi-square test. The association between GerontoNet ADR scores and ADR events was also assessed.</p><p><strong>Results: </strong>The study included 182 (53.5%) male and 158 (46.5%) female patients, with a mean age of 71.9±6.1 years. Of these, 70.9% were aged 65 to 74. A total of 78.8% of patients had ≥ 4 comorbidities. The number of drugs ranged from 3 to 28, with a mean of 10.7 drugs and a median of 10 drugs. ADRs were detected in 26 patients (7.6%), with 17 cases in females and 9 in males (p=0.044). Insulin- and diuretic-induced hypokalemia were the most frequent ADR (13 patients), followed by heparin-induced thrombocytopenia (3 patients). No significant correlation was found between ADRs and age (p=0.505), number of comorbidities (p=0.425), number of drugs (p=0.576), or GerontoNet ADR Score (p=0.530).</p><p><strong>Conclusion: </strong>Polypharmacy is prevalent at Dr. Cipto Mangunkusumo Hospital, yet the incidence of ADRs is relatively low. Most ADRs were related to high-alert drugs, while no significant correlations were found between age, polypharmacy, comorbidities, or GerontoNet Score with ADR events.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"74-80"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Six Minute Walking Test in Hospitalized Post-percutaneous Coronary Intervention Patients: Analysis of Vital Signs, Borg Scale, and Angina Scale Responses.","authors":"Adhitya Adhitya, Deddy Tedjasukmana, Eka Ginanjar, Dewi Friska","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Heart disease is one of the non-communicable diseases that cause the highest mortality. Its symptoms affect the patient's functional capacity and activities. The six-minute walking test can be done to assess a person's functional ability, response to therapy, and prognosis of chronic heart-lung conditions. The study aims to determine the safety of the six-minute walking test in inpatients after percutaneous coronary intervention by assessing the response of vital signs, Borg scale, and angina scale.</p><p><strong>Methods: </strong>This study was a one-group pre-and post-test design study with subjects of inpatients after percutaneous coronary intervention at the Integrated Cardiac Service in Cipto Mangunkusumo General Hospital Jakarta. Research subjects conducted a six-minute walking test twice with a five-minute break in between. Examination of vital signs, Borg scale, and angina scale before and after walking test. The number of subjects was 30 (27 male and 3 female) with the majority classified as a low-risk stratification.</p><p><strong>Results: </strong>The six-minute walking test was performed over two days or more in 56.7% of the subjects. The mean covered distance was 294.68 ± 57.02 meters. Vital signs of systolic and diastolic blood pressure, pulse rate, respiratory rate, and Borg rating of perceived exertion (RPE) scale increased during the test. They decreased to baseline after resting for five minutes with p-value <0.05 in the Wilcoxon Signed Rank test. Changes in saturation, dyspnea, and leg fatigue of the Borg scale, and angina scale were not statistically significant. All study subjects did not have major adverse events.</p><p><strong>Conclusion: </strong>The six-minute walking test is safe to do in inpatients after percutaneous coronary intervention with vital signs, Borg scale, and angina scale change accordingly to physiological response.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"3-10"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urological Complications of Hirschsprung-Related Crohn's Disease: A Case Report.","authors":"Kartika Anastasia Kosasih, Saut Horas Hatoguan Nababan, Andrian Setiabakti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hirschsprung disease (HSCR) is a rare congenital intestinal disease characterized by the absence of ganglion cells in the myenteric and submucosal plexuses of the intestine. Individuals with HSCR demonstrate a higher risk for inflammatory bowel disease (IBD), with Chron's disease (CD) commonly observed. Renal and urinary involvement is reported by between 4 and 23% of IBD patients, which manifests as urinary calculi, fistulas, and ureteral obstruction, which causes hydronephrosis. Those conditions can lead to a predisposition to recurrent urinary tract infections (UTIs) and should be suspected in male patients with IBD. A 26-year-old male with a history of HSCR and multiple surgeries presented with recurrent UTIs over 3 months. Upon further evaluation, he was found to have hydronephrosis in both kidneys. An MRI of the abdomen with contrast showed thickening and fibrosis in contact with the posterior wall of the rectum, causing a narrowing of the bilateral ureter. This clinical case has been reported to raise awareness of urological complications in CD patients with a history of HSCR, with recurrent UTIs as the presenting symptom.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"107-112"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olfactory and Gustatory Recovery Time Evaluation of COVID-19: A Systematic Review and Meta-Analysis.","authors":"Mohadeseh Poudineh, Amirhesam Amirbeik, Mohammad Dehghani Firouzabadi, Mahsa Hajizadeh, Farima Kahe, Sepideh Babaniamansour, Amirhossein Poopak, Farbod Zahedi Tajrishi, Niloofar Deravi, Mohammad Rahmanian, Hamidreza Ghasemirad, Mahta Malek, Masoud Noroozi, Mobina Fathi, Kimia Keylani, Ali Dehghani Firouzabadi, Ghader Dargahi Abbasabad, Forough Yazdanian, Sara Ramezanpour, Amirmohammad Babaniamansour, Faryar Zahedi Tajrishi, Soheil Mohammadi, Golnoosh Ansari, Fatemeh Dehghani Firouzabadi, David M Yousem","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Olfactory dysfunction is a common symptom of Coronavirus disease 2019 (COVID-19). In this study, we aimed to evaluate the recovery rate and duration of these symptoms in COVID-19patients.</p><p><strong>Methods: </strong>This systematic review was conducted by searching PubMed and Google Scholar from April 1st, 2020, until October 1st, 2022, using the terms ''COVID-19'' OR ''COV-2,'' OR ''Coronavirus 2'' OR coronavirus AND ''loss of smell'' OR Anosmia OR Hyposmia OR olfaction OR ''olfactory loss'' AND ageusia OR Hypogeusia OR dysgeusia OR ''gustatory loss'' OR gustation OR ''loss of taste''. The references of included studies were also manually screened. Random-effects meta-analysis was performed.</p><p><strong>Results: </strong>One hundred and twenty-five studies with test-confirmed COVID-19 infection from 31 countries were included. 62 publications which reported data on loss of taste were used to estimate patients' recovery rate in 13700 COVID-19 patients. Accordingly, the time to recovery of loss of taste among COVID-19 patients ranged from 2±0.352 to 43.6 ± 28.5 days. The estimated overall pooled recovery rate of loss of taste among COVID-19 patients was 74%. The estimated overall pooled time to recover loss of taste among COVID-19 patients was 11.44 days [95% CI 8.11, 14.77(]. 90 publications which reported data on loss of smell were used to estimate patients' recovery rate in 20027 COVID-19 patients. Accordingly, the time to recover the loss of smell among COVID-19 patients ranged from 2.44±0.352 to 31.9 ± 30.7 days The estimated overall pooled recovery rate of loss of smell among COVID-19 patients was 72%. The estimated overall pooled time to recover loss of smell among COVID-19 patients was 12.87 days [95% CI)1011, 15.64(].</p><p><strong>Conclusion: </strong>The recovery rate of loss of smell and taste among COVID-19 patients was high globally, and time to recovery of loss of smell and taste among COVID-19 patients usually was less than 2 weeks; regional differences supported the relevance of these symptoms as important markers. Health workers must consider smell and taste symptoms as suspicion indices for the empirical diagnosis of COVID-19 infection and reassure patients with their high recovery rate in a short period of time.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"18-43"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Colchicine in Reducing Reperfusion Injury in STEMI Patients Who Undergo Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial.","authors":"Birry Karim, Idrus Alwi, Mohammad Yamin, Merci Monica Pasaribu, Kuntjoro Harimurti, Nafrialdi Nafrialdi, Taufik Indrajaya, Rivaldo Rivaldo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Inflammation plays a role in ST-segment elevation myocardial infarction (STEMI), especially in reperfusion injury (RI). Colchicine, an anti-inflammatory drug, can suppress inflammation during RI. We assessed the effectiveness of administering colchicine to STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in suppressing RI events.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled clinical trial conducted in a multicenter manner at two hospitals in Jakarta with IKPP facilities from December 2022 to April 2023. STEMI patients that underwent PPCI received 2 mg of colchicine as a loading dose and a maintenance dose of 0.5 mg every 12 hours for two days or amylum at a similar dose. Patients were observed for RI events (low-flow thrombolysis in myocardial infarction (0-2) during angiography procedure, reperfusion arrhythmia, cardiogenic shock, or persistent chest pain).</p><p><strong>Results: </strong>Seventy-seven STEMI patients with a mean age of 55.2 ± 9.9 years underwent PPCI. Of these patients, 37 received colchicine, and 40 received a placebo. Most subjects were male (77.5%), suffered three-vessel disease (44.15%), and occlusion in left anterior descending coronary artery (53.24%). Colchicine was found to fail to reduce the incidence of ischemia-RI (51.5% vs. 42.4%; p = 0.437). Analysis of comorbidities (hypertension, chronic kidney disease, diabetes mellitus, and obesity) and angiography results (vessel disease, lesion diameter, and culprit artery) failed to demonstrate a statistical difference in RI. Side effects were similar in the colchicine and placebo groups (21.6% vs. 15%).</p><p><strong>Conclusion: </strong>Colchicine administration in STEMI patients undergoing PPCI failed to reduce RI.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"11-17"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scrofuloderma of the Penis: Unveiling a Rare Case of Cutaneous Tuberculosis.","authors":"Theo Audi Yanto, Edwin Raja Pardamean Lumban Tobing, Billie Edgara Herijanto, Jean Andrina Liem, Mohammad Zuhriansyah Sabran","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tuberculosis (TB) is a major worldwide health concern, with 10.4 million new cases reported each year. Extrapulmonary tuberculosis (EPTB) accounts for 20% of all occurrences, with cutaneous tuberculosis (CTS) accounting for just 1-2%. Scrofuloderma is the most prevalent kind of secondary CTS, and it commonly starts in the underlying lymph nodes, bones, or joints.Here, we describe the case of a 35 years old man presenting with a solitary nodule necrotic ulcer that happens 4 days before going to the hospital. The skin biopsy from the lesion was suggestive of TB scrofuloderma. Scrofuloderma typically presents as subcutaneous nodules that ulcerate and form sinus tracts. Diagnosis is challenging, often requiring histopathological confirmation due to potential negative microbiological results. In this case, the atypical penile appearance and the patient's history of an invasive operation aided in the diagnosis. Diabetes mellitus-related immune weakness increased the patient's susceptibility to cutaneous tuberculosis. This case demonstrates the wide range of cutaneous tuberculosis presentations and the significance of extensive diagnostic techniques, particularly in unusual patients. It also emphasizes the increased risk of tuberculosis in immunocompromised people, such as those with diabetes mellitus.</p>","PeriodicalId":6889,"journal":{"name":"Acta medica Indonesiana","volume":"57 1","pages":"124-127"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}